Immix Biopharma, Inc. reported a net loss of $4,542,528 for the three months ended March 31, 2025, a decrease from $5,331,064 in the same period last year. This improvement was primarily due to a $1.7 million grant reimbursement from the California Institute for Regenerative Medicine, which offset research and development expenses. The company's total assets were $19,892,040, and cash and cash equivalents stood at $15,921,101, indicating sufficient liquidity to fund operations for at least the next 12 months.